Trial Profile
A Phase 1 Randomized Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Relative Bioavailability of Subcutaneous Injection Versus Intravenous Infusion in Participants With Advanced Melanoma (KEYNOTE-555)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms KEYNOTE-555
- Sponsors Merck Sharp & Dohme Corp.
- 12 Dec 2023 Status changed from active, no longer recruiting to completed.
- 19 Jan 2023 Planned End Date changed from 4 Feb 2023 to 4 Dec 2023.
- 19 Jan 2023 Planned primary completion date changed from 4 Feb 2023 to 4 Dec 2023.